Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (297) 297
Publication (21) 21
Patent (9) 9
Conference Proceeding (7) 7
Book Chapter (3) 3
Book / eBook (2) 2
Dissertation (1) 1
Journal / eJournal (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (122) 122
index medicus (80) 80
male (71) 71
female (65) 65
middle aged (57) 57
aged (55) 55
venous thromboembolism (50) 50
prevention (47) 47
anticoagulants - therapeutic use (44) 44
risk factors (44) 44
thromboembolism (41) 41
anticoagulants (40) 40
adult (39) 39
thrombosis (38) 38
hematology (37) 37
peripheral vascular disease (34) 34
cancer (33) 33
atrial fibrillation (32) 32
treatment outcome (32) 32
abridged index medicus (30) 30
deep-vein thrombosis (30) 30
neoplasms - complications (29) 29
venous thromboembolism - prevention & control (29) 29
stroke (28) 28
oncology (26) 26
prophylaxis (26) 26
rivaroxaban (26) 26
warfarin (26) 26
care and treatment (25) 25
double-blind method (24) 24
hemorrhage - chemically induced (24) 24
surgery (24) 24
drug therapy (22) 22
mortality (22) 22
medicine, general & internal (21) 21
anticoagulants - adverse effects (20) 20
cardiac & cardiovascular systems (20) 20
molecular-weight heparin (20) 20
patients (20) 20
aged, 80 and over (18) 18
anticoagulants - administration & dosage (18) 18
venous thromboembolism - drug therapy (18) 18
venous thrombosis (18) 18
bleeding (17) 17
pulmonary embolism (17) 17
risk (17) 17
risk assessment (17) 17
heparin (16) 16
heparin, low-molecular-weight - therapeutic use (16) 16
pulmonary-embolism (16) 16
therapy (16) 16
venous thromboembolism - etiology (16) 16
venous thrombosis - prevention & control (16) 16
administration, oral (15) 15
enoxaparin (15) 15
hemorrhage (15) 15
prospective studies (15) 15
pulmonary embolism - prevention & control (15) 15
unfractionated heparin (15) 15
dosage and administration (14) 14
health aspects (14) 14
management (14) 14
recurrence (14) 14
registries (14) 14
time factors (14) 14
fibrinolytic agents - therapeutic use (13) 13
thromboprophylaxis (13) 13
guidelines (12) 12
postoperative complications - prevention & control (12) 12
anticoagulation (11) 11
chemotherapy (11) 11
health risk assessment (11) 11
incidence (11) 11
life sciences (11) 11
practice guidelines as topic (11) 11
research (11) 11
usage (11) 11
analysis (10) 10
cardiac arrhythmia (10) 10
cardiovascular (10) 10
diagnosis (10) 10
internal medicine (10) 10
neoplasms - drug therapy (10) 10
neoplasms - mortality (10) 10
pulmonary embolism - mortality (10) 10
veins & arteries (10) 10
venous thromboembolism - epidemiology (10) 10
adolescent (9) 9
atrial fibrillation - drug therapy (9) 9
fibrinolytic agents - adverse effects (9) 9
follow-up studies (9) 9
human necessities (9) 9
hygiene (9) 9
medical or veterinary science (9) 9
medicine (9) 9
preparations for medical, dental, or toilet purposes (9) 9
randomized controlled trials as topic (9) 9
thromboembolism - prevention & control (9) 9
warfarin - therapeutic use (9) 9
clinical neurology (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Thrombosis and cancer
by Lugassy, Gilles and MyiLibrary
2004, 1, ISBN 9781841842875, 241
It is common knowledge that thromboembolic disease is often the earliest manifestation and almost the most frequent complication of cancer. Recent studies have... 
Complications | Thrombosis | Cancer | Clinical & internal medicine
eBook
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer
by Farge, Dominique, Prof and Bounameaux, Henri, Prof and Brenner, Benjamin, Prof and Cajfinger, Francis, MD and Debourdeau, Philippe, MD and Khorana, Alok A, Prof and Pabinger, Ingrid, Prof and Solymoss, Susan, MD and Douketis, James, Prof and Kakkar, Ajay, Prof
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 10, pp. e452 - e466
Summary Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at an increased risk of developing VTE... 
Hematology, Oncology and Palliative Medicine | PERIOPERATIVE THROMBOPROPHYLAXIS | ONCOLOGY | MOLECULAR-WEIGHT HEPARIN | VENA-CAVA FILTER | PULMONARY-EMBOLISM | ANTITHROMBOTIC THERAPY | DEEP-VEIN THROMBOSIS | CANADIAN CONSENSUS RECOMMENDATIONS | LONG-TERM TREATMENT | UNFRACTIONATED HEPARIN | BLEEDING COMPLICATIONS | Neoplasms - complications | Venous Thromboembolism - prevention & control | Administration, Oral | Humans | Anticoagulants - therapeutic use | Catheterization, Central Venous - adverse effects | Venous Thromboembolism - drug therapy | Practice Guidelines as Topic | Practice guidelines (Medicine) | Cancer patients | Anticoagulants (Medicine) | Drug therapy | Thromboembolism | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
by Eriksson, Bengt I and Borris, Lars C and Friedman, Richard J and Haas, Sylvia and Huisman, Menno V and Kakkar, Ajay K and Bandel, Tiemo J and Beckmann, Horst and Muehlhofer, Eva and Misselwitz, Frank and Geerts, William and RECORD1 Study Grp and RECORD1 Study Group and Institutionen för kliniska vetenskaper, sektionen för anestesi, biomaterial och ortopedi and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Institute of Clinical Sciences, Section for Anesthesiology, Biomaterials and Orthopaedics and Sahlgrenska Academy
The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry
by Kakkar, A.K and Mueller, I and Bassand, J.P and Fitzmaurice, D.A and Goldhaber, S.Z and Goto, S and Haas, S and Hacke, W and Lip, G.Y and Mantovani, L.G and Turpie, A.G.G and Eickels, M. van and Misselwitz, F and Rushton-Smith, S and Kayani, G and Wilkinson, P and Verheugt, F.W.A and et al and GARFIELD Registry Investigators and for the GARFIELD Registry Investigators
Plos One, ISSN 1932-6203, 2013, Volume 8, Issue 5, p. e63479
BACKGROUND: Limited data are available on the characteristics, clinical management, and outcomes of patients with atrial fibrillation at risk of stroke, from a... 
PREDICTING STROKE | ACC/AHA/ESC 2006 GUIDELINES | MANAGEMENT | TASK-FORCE | WARFARIN | PROGNOSIS | MULTIDISCIPLINARY SCIENCES | EURO HEART SURVEY | PREVALENCE | THROMBOEMBOLISM | SOCIETY | Prospective Studies | Atrial Fibrillation - drug therapy | Humans | Risk Factors | Atrial Fibrillation - complications | Molecular Sequence Data | Male | Stroke - drug therapy | Contraindications | Randomized Controlled Trials as Topic | Stroke - etiology | Vitamin K - antagonists & inhibitors | Fibrinolytic Agents - therapeutic use | Female | Registries | Aged | Atrial Fibrillation - diagnosis | Stroke (Disease) | Medical research | Care and treatment | Atrial fibrillation | Medicine, Experimental | Anticoagulants (Medicine) | Health aspects | Risk factors | Heart | Drugs | Therapy | Cardiac arrhythmia | Demography | Ethics | Demographics | Fibrillation | Cardiology | Age | Vitamin K | Hypertension | Anticoagulants | Stroke | Enrollments | Health risks | Patients | Thrombosis | Medicine | Hospitals | Adults | Diabetes | Clinical medicine | Risk management
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
by Kakkar, Ajay K, Prof and Brenner, Benjamin, Prof and Dahl, Ola E, MD and Eriksson, Bengt I, MD and Mouret, Patrick, MD and Muntz, Jim, MD and Soglian, Andrea G, MD and Pap, Ákos F and Misselwitz, Frank, MD and Haas, Sylvia, Prof and RECORD2 Investigators and Institutionen för kliniska vetenskaper, sektionen för anestesi, biomaterial och ortopedi and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Institute of Clinical Sciences, Section for Anesthesiology, Biomaterials and Orthopaedics and Sahlgrenska Academy
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
by Cohen, Alexander T, Dr and Tapson, Victor F, MD and Bergmann, Jean-Francois, Prof and Goldhaber, Samuel Z, Prof and Kakkar, Ajay K, Prof and Deslandes, Bruno and Huang, Wei, MS and Zayaruzny, Maksim, MD and Emery, Leigh and Anderson, Frederick A, Prof and ENDORSE Investigators
Lancet, The, ISSN 0140-6736, 2008, Volume 371, Issue 9610, pp. 387 - 394
Summary Background Information about the variation in the risk for venous thromboembolism (VTE) and in prophylaxis practices around the world is scarce. The... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | PLACEBO | PULMONARY-EMBOLISM | GUIDELINES | PREVENTION | THROMBOPROPHYLAXIS | ILL MEDICAL PATIENTS | Guideline Adherence - statistics & numerical data | Cross-Sectional Studies | Humans | Middle Aged | Risk Factors | Postoperative Complications - prevention & control | Anticoagulants - therapeutic use | Male | Hospitalization | Contraindications | Medical Audit - statistics & numerical data | Venous Thromboembolism - etiology | Venous Thromboembolism - prevention & control | Female | Aged | Prevention | Research | Thromboembolism | Risk factors | Hospitals | Mortality | Medical treatment | Data collection | Patients | Trauma | Chronic illnesses | Veins & arteries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
by Eikelboom, John W and Connolly, Stuart J and Bosch, Jackie and Dagenais, Gilles R and Hart, Robert G and Shestakovska, Olga and Diaz, Rafael and Alings, Marco and Lonn, Eva M and Anand, Sonia S and Widimsky, Petr and Hori, Masatsugu and Avezum, Alvaro and Piegas, Leopoldo S and Branch, Kelley R.H and Probstfield, Jeffrey and Bhatt, Deepak L and Zhu, Jun and Liang, Yan and Maggioni, Aldo P and Lopez-Jaramillo, Patricio and O’Donnell, Martin and Kakkar, Ajay K and Fox, Keith A.A and Parkhomenko, Alexander N and Ertl, Georg and Störk, Stefan and Keltai, Matyas and Ryden, Lars and Pogosova, Nana and Dans, Antonio L and Lanas, Fernando and Commerford, Patrick J and Torp-Pedersen, Christian and Guzik, Tomek J and Verhamme, Peter B and Vinereanu, Dragos and Kim, Jae-Hyung and Tonkin, Andrew M and Lewis, Basil S and Felix, Camilo and Yusoff, Khalid and Steg, P. Gabriel and Metsarinne, Kaj P and Cook Bruns, Nancy and Misselwitz, Frank and Chen, Edmond and Leong, Darryl and Yusuf, Salim and COMPASS Investigators
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1319 - 1330
In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events... 
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights